{"classes":[{"categories":[{"measurements":[{"comment":"NA - The follow-up was too short that the quantiles of the survival distribution could not be estimated.","groupId":"OG000","lowerLimit":"10.4","upperLimit":"NA","value":"14.9"},{"comment":"NA - The follow-up was too short that the quantiles of the survival distribution could not be estimated.","groupId":"OG001","lowerLimit":"11.4","upperLimit":"NA","value":"15.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Overall survival was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact. Patients not known to have died were censored for 'Lost to follow-up' if the time between their last contact date and the analysis cut-off date was longer than 3 months and 2 weeks (104 days) during the first year after study evaluation completion, and longer than 6 months and 2 weeks (194 days), thereafter. The 1-year survival rate was obtained from the Kaplan-Meier analysis of overall survival, and its variance was estimated by Greenwood's formula.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: Consisted of all patients who were randomized to one of the two treatment arms","reportingStatus":"POSTED","timeFrame":"12 months","title":"1-year Survival Rate (Phase Llb)","type":"SECONDARY","unitOfMeasure":"months"}